Dr Reddy's launches Remdesivir under brand name 'Redyx' for Covid-19 treatment in India

According to a press release from the drug maker, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news